<SUBMISSION>
<ACCESSION-NUMBER>0001193125-09-203872
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20090930
<ITEMS>1.01
<ITEMS>2.03
<ITEMS>3.02
<ITEMS>9.01
<FILING-DATE>20091006
<DATE-OF-FILING-DATE-CHANGE>20091006
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>PRO PHARMACEUTICALS INC
<CIK>0001133416
<ASSIGNED-SIC>2834
<IRS-NUMBER>043562325
<STATE-OF-INCORPORATION>NV
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>001-31791
<FILM-NUMBER>091107026
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>189 WELLS ST
<STREET2>STE 200
<CITY>NEWTON
<STATE>MA
<ZIP>02459
<PHONE>6175590033
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>189 WELLS ST
<STREET2>STE 200
<CITY>NEWTON
<STATE>MA
<ZIP>02459
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>Form 8-K </B>
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P
STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Current Report </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman"
SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>September&nbsp;30, 2009 </B>
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Date of Report </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Date of earliest event reported) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman"
SIZE="6"><B>PRO-PHARMACEUTICALS, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of Registrant as specified in its charter) </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Nevada</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>000-32877</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>04-3562325</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or other jurisdiction of</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"
ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>incorporation or organization)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission File Number)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7 Wells Avenue </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"
ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Newton, Massachusetts 02459 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal
executive offices) (Zip code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(617) 559-0033 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"
ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Registrant&#146;s telephone number, including area code) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P
STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Former name or former address, if changed since last report) </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE> <P
STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;1.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Entry into a Material Definitive Agreement </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In a Current Report on Form 8-K filed with the Commission on February&nbsp;18, 2009 (the &#147;<U>February 18, 2009 Form 8-K Current Report</U>&#148;), Pro-Pharmaceuticals, Inc., a Nevada corporation (the
&#147;<U>Company</U>&#148;), reported, among other things, that the Company (i)&nbsp;had entered into a Securities Purchase Agreement (the &#147;<U>Purchase Agreement</U>&#148;) and related agreements on February&nbsp;12, 2009 with 10X Fund, L.P., a
Delaware limited partnership (the &#147;<U>Purchaser</U>&#148;) and (ii)&nbsp;had completed an initial closing under the Purchase Agreement. The February&nbsp;18, 2009 Form 8-K Current Report also reported that under the Purchase Agreement the
Company agreed to issue and sell to the Purchaser, and the Purchaser agreed to purchase, at one or more subsequent closings: (i)&nbsp;up to 2,100,000 shares of Series B-2 Preferred Stock (the &#147;<U>Series B-2 Preferred Stock</U>&#148;)
convertible into up to 8,400,000 shares of the Company&#146;s common stock, par value $0.001 per share (the &#147;<U>Common Stock</U>&#148;); (ii)&nbsp;Class&nbsp;A-1 Warrants exercisable to purchase up to 4,200,000 shares of Common Stock (the
&#147;<U>Class A-1 Warrants</U>&#148;); (iii)&nbsp;Class&nbsp;A-2 Warrants exercisable to purchase up to 4,200,000 shares of Common Stock (the &#147;<U>Class A-2 Warrants</U>&#148;); and (iv)&nbsp;Class B Warrants exercisable to purchase up to
16,800,000 shares of Common Stock (the <U>Class B Warrants</U>&#148;) for an aggregate purchase price of $4.2 million (less the origination fees and expenses described below). </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On August&nbsp;11, 2009, the Company and the Purchaser entered in to a letter agreement (the &#147;Letter Agreement&#148;), pursuant to
which the parties amended the Purchase Agreement and agreed to the terms of an amendment to the Certificate of Designation of Preferences, Rights and Limitations for the Series B-1 Convertible Preferred Stock and Series B-2 Convertible Preferred
Stock (the &#147;Designation Certificate Amendment&#148;). Among the changes contained in the terms of the Letter Agreement and the Designation Certificate Amendment was an extension of the final purchase date under the Purchase Agreement from
August&nbsp;11, 2009 to February&nbsp;11, 2010. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In a subsequent closing on September&nbsp;30, 2009, pursuant to the Purchase
Agreement, the Company issued and sold an aggregate of (i)&nbsp;162,500 shares of Series B-2 Preferred Stock convertible into 650,000 shares of Common Stock, (ii)&nbsp;Class&nbsp;A-1 Warrants exercisable to purchase 325,000 shares of Common Stock,
(iii)&nbsp;Class&nbsp;A-2 Warrants exercisable to purchase 325,000 shares of Common Stock, and (iv)&nbsp;Class B Warrants exercisable to purchase 1,300,000 shares of Common Stock for gross proceeds of $325,000. Net proceeds of these sales were
approximately $305,200 after reimbursement of the Purchaser&#146;s expenses (including legal expenses) in connection with the subsequent closings and an origination fee in the amount of three percent of the gross proceeds from the sale of these
securities. The terms and conditions of the Purchase Agreement, the Certificate of Designation of Preferences, Rights and Limitations for the Series B-1 Convertible Preferred Stock and Series B-2 Convertible Preferred Stock, the &#147;Original
Designation Certificate&#148;, that established the Series B-2 Preferred Stock, the Series A-1 Warrants, the Series A-2 Warrants and the Series B Warrants were disclosed in the February&nbsp;18, 2009 Form 8-K Current Report including the exhibits
thereto. The terms and conditions of the Letter Agreement and the Designation Certificate Amendment were described in the Company&#146;s Quarterly Report on Form 10-Q for the quarter ended June&nbsp;30, 2009, and copies of the Letter Agreement and
Designation Certificate Amendment were filed as exhibits thereto. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The description of the Class&nbsp;A-1 Warrants, the
Class&nbsp;A-2 Warrants and the Class B Warrants issued by the Company in the subsequent closing reported in this report is not complete and is qualified in its entirety by reference to the full text of the Form of Class&nbsp;A-1 Warrants, the Form
of Class&nbsp;A-2 Warrants and the Form of Class B Warrants, copies of which are filed as Exhibit 4.1, Exhibit 4.2 and Exhibit 4.3, respectively, in the February&nbsp;18, 2009 Form 8-K Current Report and incorporated herein by reference. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;2.03</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Creation of Direct Financial Obligation or an Obligation under an Off-Balance Arrangement of Registrant. </B></FONT></TD></TR></TABLE> <P
STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the terms of the Original Designation Certificate, as amended by the Designation Certificate Amendment, upon notice of not less than 30
trading days, a holder may require the Company to redeem, in whole or in part, (i)&nbsp;the Series B-1 Preferred Stock at any time on or after September&nbsp;12, 2010 and (ii)&nbsp;the Series B-2 Preferred Stock at any time on or after two years
from the date of issuance of such shares of Series B-2 Preferred Stock. The redemption price will be equal to the sum of the stated value of the Series B Preferred Stock, plus all accrued but unpaid dividends thereon, as of the redemption date.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the Company fails for any reason to pay the redemption price in cash on the redemption date, then the holders requesting
redemption may, at their sole option, automatically convert their shares of Series B Preferred Stock into a promissory note bearing interest at the rate of 15%&nbsp;per year and secured by a lien on all assets of the Company. The Company has
executed a promissory note, security agreement and escrow agreement, copies of which were filed as Exhibits 10.2, 10.3 and 10.4, respectively, to the February&nbsp;18, 2009 Current Report on Form 8-K and are incorporated herein by reference, which
will be held in escrow and released to the holders upon the occurrence of such an event. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;3.02</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Unregistered Sales of Equity Securities. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The information contained in Item&nbsp;1.01 of this report is incorporated by reference into this Item&nbsp;3.02. The Series B-2 Convertible Stock and warrants sold at the subsequent closing on
September&nbsp;30, 2009, under the Purchase Agreement were issued in reliance on the exemption from registration under Section&nbsp;4(2) of the Securities Act of 1933, as amended (the &#147;<U>Securities Act</U>&#148;), and Rule 506 of Regulation D
promulgated thereunder. The Series B-2 Preferred Stock and warrants were not registered under the Securities Act and are &#147;restricted securities&#148; as such term is defined in Rule 144 under the Securities Act. </FONT></P> <P
STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Statements and Exhibits. </B></FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Financial Statements of Businesses Acquired. </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Not applicable. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pro Forma Financial Information. </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman"
SIZE="2">Not applicable. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Shell Company Transactions </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Not
applicable. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibits. </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;4.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Class A-1 Common Stock Purchase Warrant*</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;4.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Class A-2 Common Stock Purchase Warrant*</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;4.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Class B Common Stock Purchase Warrant*</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">News release dated October 6, 2009, &#147;Pro-Pharmaceuticals Closes $325,000 Tranche Brings Total to $3.8 Million of $6 Million Private Placement.&#148;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the Company&#146;s Current Report on Form 8-K filed with the Commission on February&nbsp;18, 2009. </FONT></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURE </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">PRO-PHARMACEUTICALS, INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/<SMALL>S</SMALL>/&nbsp;&nbsp;&nbsp;&nbsp;A<SMALL>NTHONY</SMALL> D.
S<SMALL>QUEGLIA&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</SMALL></FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Anthony D. Squeglia</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Chief Financial Officer</B></FONT></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: October&nbsp;6, 2009 </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:28pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;4.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Class&nbsp;A-1 Common Stock Purchase Warrant.*</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;4.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Class&nbsp;A-2 Common Stock Purchase Warrant.*</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;4.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Class B Common Stock Purchase Warrant.*</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">News release dated October 6, 2009, &#147;Pro-Pharmaceuticals Closes $325,000 Tranche Brings Total to $3.8 Million of $6 Million Private Placement.&#148;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the Company&#146;s Current Report on Form 8-K filed with the Commission on February&nbsp;18, 2009. </FONT></TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dex991.htm
<DESCRIPTION>NEWS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>News Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px">

<IMG SRC="g89919ex99_1pg.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PRO-PHARMACEUTICALS CLOSES $325,000 TRANCHE; </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>BRINGS TOTAL TO $3.8 MILLION OF $6.0 MILLION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>PRIVATE PLACEMENT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Newton, MA (October 6, 2009) Pro-Pharmaceuticals, Inc. (OTCBB:
PRWP)</B> (the &#147;Company&#148;), today announced that it has closed a $325,000 tranche of a private placement of up to $6.0 million with 10X Fund, L.P., which is purchasing unregistered Series B convertible preferred stock and warrants. This
tranche brings the total raised to date to approximately $3.8 million. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">At the closing, which occurred on September&nbsp;30, 2009, the Company
issued and sold 162,500 shares of Series B-2 preferred stock convertible into 650,000 shares of common stock, a Class&nbsp;A-1 and a Class&nbsp;A-2 warrant each exercisable to purchase 325,000 shares of common stock and a Class B warrant exercisable
to purchase 1,300,000 shares of common stock, for a gross purchase price of $325,000. Net proceeds were approximately $305,000. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company
expects to use the proceeds from the financing for partnership development and approvals in countries with their own approval process, as well as for general corporate purposes. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Series B Preferred Stock, the Class&nbsp;A-1 Warrants, the Class&nbsp;A-2 Warrants and the Class B Warrants, including the common stock underlying the Series B Preferred Stock and warrants, have not
been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. </FONT></P> <P
STYLE="margin-top:18px;margin-bottom:0px;padding-bottom:3px;"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About DAVANAT<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and Galectin Therapeutics </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:3px;"><FONT STYLE="font-family:Times New Roman"
SIZE="2">DAVANAT<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, the Company&#146;s lead product candidate, is a carbohydrate polymer designed to interact
with Galectin receptors which are up-regulated on all solid tumors.&nbsp;Current research indicates that galectins affect cell development and play important roles in cancer, including tumor cell survival, angiogenesis and tumor
metastasis.&nbsp;DAVANAT<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> is a drug that is not yet approved for commercial use by the FDA. </FONT></P> <P
STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Pro-Pharmaceuticals, Inc. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman"
SIZE="2">Pro-Pharmaceuticals, OTCBB: PRWP, is focused on the commercialization of Galectin therapeutics for advanced treatment of cancer and fibrosis.&nbsp;Initially, the product pipeline is focused on increasing the efficacy and decreasing the
toxicity of chemotherapy drugs.&nbsp;The Company is headquartered in Newton, Mass.&nbsp;Additional information is available at www.pro-pharmaceuticals.com. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>FORWARD LOOKING STATEMENTS:</B> Any statements in this news release about future expectations, plans and prospects for the company, including without limitation statements containing the words
&#147;believes,&#148; &#147;anticipates,&#148; &#147;plans,&#148; &#147;expects,&#148; &#147;intends,&#148; and similar expressions, constitute forward-looking statements as defined in the &#147;safe harbor&#148; provisions of the Private Securities
Litigation Reform Act of 1995. These forward-looking statements are based on management&#146;s current expectations and are subject to a number of factors and uncertainties, which could cause actual results to differ materially from those described
in such statements. We caution investors that actual results or business conditions may differ materially
</FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
from those projected or suggested in forward-looking statements as a result of various factors including, but not limited to, the following: uncertainties as to the utility and market for our
potential products; uncertainties associated with pre-clinical and clinical trials of our product candidates; and uncertainties as to the results of the financing. More information about those risks and uncertainties is contained in the
Company&#146;s most recent quarterly or annual report and in the Company&#146;s other reports filed with the Securities and Exchange Commission. While the Company anticipates that subsequent events may cause the Company&#146;s views to change, the
Company disclaims any obligation to update such forward-looking statements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Contact: Pro-Pharmaceuticals, Inc., Anthony D. Squeglia:
617.559.0033; squeglia@pro-pharmaceuticals.com. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">DAVANAT is a registered trademark of Pro-Pharmaceuticals. </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g89919ex99_1pg.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g89919ex99_1pg.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`-@%_`P$1``(1`0,1`?_$`+L```$#!`,!````````
M```````'"`D"!`8*`0,%"P$!``$%`0$!``````````````4"`P0&!P$("1``
M``<``00"`0,#`@,$"P```0(#!`4&!P@`$1()(1,4,14*42(602,D%QAA,S<X
MD;$R0D,TM':V)W<1``(!`@4"`P4%!`8(!04!``$"`Q$$`"$2!08Q!T$B$U%A
M,A0(<8&1L2.AP3,5T4)2=#46\&)RPD-S)#;ADK*S-()3PR5E)__:``P#`0`"
M$0,1`#\`W^.F&#IA@Z88.F&#IA@Z88;9RJY<8%PMR:8V;D/?8ZDU&-`[>-:F
M_P"-LUPG!1.JSJU)KB!OW&RV.0\.R;=`OBF7NJL=)`BBI)WCO&]YY3N*[7LD
M+2W+9D]$1?%Y&.2J/:>O0`D@'PD`5.-![FM[CM[]CO(/.*@B5YDO%^%TVO/:
MEC,<]35?6)PRDR'CK7J\RT[%L=B3$H*MF")@BHHW_=%67`SM3[2X%VQV?@]M
M\R:7/('2CSD9*",TA4_"O@6/G?QH/*('D3EMCN_9Z#_EC84X">VF2HP0>-\I
MY5U,TM/\>+JNP+E4=S540`"(-(R^@F4[B:K[<H`5.3*!WC0@=G`+)_[J7/.X
M_9F+<#)OG$$6.^-6DMADLAZEH?!7/C'DK?U=)R.C\;YH]OIL=X):#HLO4K[G
M]J_ZW4>-1F-E*+E(R;C6,Q#2+&7B)1HW?QDI&.T'\=(L7215FKUB]:J*MG;5
MRB<#IJ)F,0Y1`0$0'KY7FAEMY6@G5DF1B&5@0RD9$$',$'J#F,=51TD021D,
MA%00:@@^(.+[JWBK!TPP=,,'3#!TPP=,,'3#!TPP=,,'3#!TPP=,,'3#!TPP
M=,,'3#!TPP=,,'3#!TPP=,,'3#!TPP=,,'3#!TPP=,,'3#!TPP=,,'3#!TPP
M=,,'3#!TPP=,,'3#!TPQ;E=M3*$1*Y;F54`PII%63%0X$#N<2$`WD8"`/SV#
MXZK,;@:BITCW84..\1`H"8P@4H`(B(B```!^HB(_``'5'7(=<,=9%T%#>*:R
M2ANPCXD4(8W8.W<>Q1$>P=^JBK#,@@88[>J<,8XYN%29SK:KO+37&MF>%3,S
MKKF;C$)UV54JATC-HA5T607*H1(XE$J8]P*(A^@]9:6%]);&\CAE:T7JX1B@
MIUJU-(ZCQ\<5!'*Z@#I]M,L9'UB8IQ\K_P!I/(W;^1?-WD(ZVF^35N)F.QZK
MF.=P3LWXE=H5(J-ZFH&(@JQ7FX)QT5]S*,24>N"D%U(.>ZSA10_;M^A/;[9-
MIV3B=DNU0I%\Q:PRR,,VDD>-69G;J<R=(Z*,E`&,=C5L-&Q'_P`8LP_^]X#_
M`.M)UN3_``G[,0W(/\#N_P#D/^6)N^L;'!,3^^CC7=&D+MI^*2-ID)+,H&@)
MW.NUA^<';>NSJEIC8QT>"76`SF,CWS>04,LT3,#8RW94"%.)Q-\W_4!LNUQV
M%IOT4*KNTESZ3R#(NGILPU@9,00*,?-3*M*4Z3V^O;IKB:P9R;18M2J<])U`
M9>P&N8Z5SQL>'612$`4523$0[@!U"D$0_3N`&$!$._7R^%9N@)QU/'84P&`#
M%$#%,`&*8H@(&`0[@("'P("'5/3(]<,4@HF)Q3`Y!4`.XI@8OF`?'R)>_D`?
M(=>T-*TRPP?8F!P3$Y`4$/($_(/,2_/R!>_D(?'2AI6F6&*^O,,4$4(H'DF<
MAP`1`1(8#``A^H=RB(=PZ]((ZX8Y.<B9?)0Y2%#MW,<P%*'?X#Y,(!\CT`)-
M!F<,4D525[BDHFIV^!\#E/V[_IW\1'MWZ%67J",,5F,4A1,8P%*`=Q,80`H!
M_41'L`!UX`3D.N&`IBF`#%$#%,`"4Q1`0$!^0$!#X$!#H01D>N&*2*)J!Y)G
M(H7OV\B&`P=P_4.Y1$.X=^O2",CD<,5"(%`3&$"E*`B(B(````=Q$1'X``#K
MSKD.N&."F*<H&(8IBF#N4Q1`Q1#^H"'<!#H00:'KABKIACK*JD8YDRJ)F.7O
MY$*<HG+V^!\B@/<.PCU[I8"I!IA@.LBD(`HJFF(_(`<Y2"(!^O;R$._;H%9O
MA!.&.2*IJ@(IJ$4`![")#E.`#_01*(]AZ$%>H(PP`H03F3`Y!.4`$Q`,`G*`
M_H)B@/<`'I0TK3+#!]B8G%,#D%0`[BGY%\P#X^1+W\@#YZ4-*TRPQ2=P@F;Q
M462(;X'Q.H0INP_H/8P@/SUZ%8Y@$C#')%D51$$U4U!#Y$"'*<0`?T[^(CV[
M]>%67X@1ACD%""<4P.05"@`F(!@$Y0']!$O?N`#TH:5\,,5]>88MT'C1SW_&
M=-W'81`?H725["7MY`/UF-V$O?Y_IU6T;I\:D?:*8]H<=YC`4!,80*4H")C&
M$```#Y$1$?@``.J.N0ZX\QP4Q3E`Q#%.4?T,40,4?]/@0[@/SUZ00:'KAC@R
MB9!*!SD()Q[$`QBE$X_'P4!$!,/S_IT`)Z##%?7F&,:F[G3ZTZ9,K':ZU7WL
ME\1S2;G8N*=/Q^PB/_!-W[I!5U_O*%)_M@;^XP!^H]9=O87UVC26D,TL:?$4
M1F"^.9`(&6>>*E1VS4$@>P8R7K$Q3@Z88.F&*"*$4#R3.10O?MY$,!@[A^H=
MRB(=PZ]((R(H<,`*IF.*8*$%0H=S)@<HG*'Q\B4!\@#^X/\`T]*&E:&F&.?,
MGG]?F7[.WEX>0>?C^GEX]_+MW_UZ4-*^&&*NO,,=15T#F\"+)&/W$/`JA#&[
ME[^0>("(]P[?/515@*D&F&.WJG#'RPL:C>&R?K8VC5+9MU_J7LHKN_PT7Q:K
ME&TJ^EO$_6Q0S84TDZ9$O%&*$.X<2DZ8DN'X[T'C1-)%4YRD;+?LQO\`-ST]
MVMOV6RV^UG[2R[8[;C)-!#Z*25G_`.*PJ6`6&L7F32Q9E`)=>ES-=#<$B5%.
MW&/SD@4KGX^WIEC?8UZ7V24](^DSF]H2$7NS[UO6J1U1)X16/FVNAK<?7J]E
M/*(E!!6/GOW@5#NTR@F*#L3E`I?$`#\U-C@V"'ZAK2VXR5?C:\LC6VIYD,`O
M0(])SU)IH%.=5H:FN-)A$(WE5@SA^8&GV4U9?=C2=Q>FXU=^-/`]'U\6?D7/
M^X]SK;:6TQ#-)[79*J4>F-[O>6*,[H3J024S^HQL?`-Z^NHHT6!J=@LY_<"G
M34.4/T(Y!N&_[=R[DK=T(=JB["BQ*VYG2V62:4PPDI"%I-*S.9P`PU!PGI4(
M!QM\SRI<3?/",;3H\M0M2:#IXG.O7[L;R?MGY@7?@GZ[MPY"U!%@\U2!KU:J
M5.=N&X.(J+O-_G8>F-;0HS4*";M"L+3"LDBW4+]3A5LFDH'@<W7YT=DN"[=W
M([I[=Q:^++LTLLDLH!HS0PHTICKX&0*(RPS4,6&8&--VNT2]W!+=OX1))^P"
MM/OZ8A=QC^.SAN]<(H+;]:TS8;GS^W;+X_=$>13O3+""M;T^^0*%YK,4A%*.
M2Q\E`QSN10:2#EV!W[D3N%FZ[3R0(W[_`+_]5'(^-=PY..[)9V%OVRVV\:S-
MB+=/U+>%S#(Q:FI78*615HBT565Z,6EI=^F@O##$J"Q1M.F@S`-#]_L\/MQ(
M#_'DY8:URGX`));G.2=MU#`=;NV#3MTG9AS/V&W,JVR@+)"2EAFGKEVZEI=A
M'6PL8HZ.<3.BQY5A$QCF,/,?JDX5LG#.YQ;CD:0;/N=C%>)$BA$B,A>-U1``
M%5FC]0*!Y2Y7("F,'?K6*VOOT0!'(@:@R`K49?A7[\:(7/YJ#'G=S1:!]@`W
MY5;XF'VAV4_\3[,;^\.Q>P_W?T#KZ*X:VOB&U-[=NM__`&EQKAZX?/PC]9->
MV>K8AR!<^P+A!E3R=G#3"F+Z;I'['K,*I`6J4A`BI>",L!T)"7+$@[:`!!!1
MJY2.'?RZU'?>Y<VS[I<;4FQ[O<K`^GU8HB8WR!JAT&JYTK4UIC!W6V%UM<]N
M9$CUQ,-3&BK4=3[AXX?IR(P%E@,O5XEEMF/;66RQDI)*2./V(UA85\8UVS:E
M8SJIB%!J[D`=BH@4!$3$1./;X#O,<3Y7)RE)VDVZ]V_T2HI<*5+ZM7P5`KIT
MY_:,<2W;:5VIHPMQ!<:Z_P`,UTTIUS/6N7V'$EWHM_\`,5L?_P#%4O\`\YK_
M`%S/Z@_^V+'^_P#_`.)\;/V\_P`4G_N_^^N$O]S]>XM7/W!\!Z?S9NR=%XP2
MG%[97.@3#_1+#F40A(QSZZ/:=^79ZY*1+]DHYMK=DD0"JE^\Q@2'N4W8=G[`
M77,MO[%<FO\`M[;FYY@F\6H@58$N&*L(A+2.164TB+DU&69\,?0FT-=)M<SV
M2ZIQ(*9`_P!FN1]U<*1_'BG94^R>Q6EX%>-(TKUL4S4J\RXK6_1G]AETAGUO
MW?\`RR-H\M:$FTFXA"1B34[@@))_V?AKK$(Y<K">)^J2W@&P\5W#DUO:6G=F
MXLW.XQ0!%.@:?3:98R5#ZBP4U.?J*I*(M*-]"^C;O,%7<&7S@>S*E:?Z=<-I
MVSG9CO`3^1ERRUWD`]T4^?2?%C,J)&L*%6Y.[O"6::I>+33512OM'K<C5D+&
M`="=R`#XJ"4HA_N"(;;Q[MOOW<SZ5-DV/C"VO\T3>;B9C-(L0]-);M#YR#4U
M=:+[*GPQD0V4M[L$4<&GU/5)S-,JM_3B]P;G7CO/K^1;QEU[`'FB$SV,XB:3
M1)%A?:W)4EZ:SP<%JLT[43K[MXX(Z9`PL+7P<B`>:@&*`?[8"-ODO;C?NV?T
MJ[OL?)UM?YH^^03*89%E'IN]LHJX`H=2-5?`4/CCR:RELM@DCGT^IZH.1KD2
MO]&)W_<9RT-PQ]=O(O7(I_\`@WV7JA\LRH$S*%>JZ1I_G5()U&@EV4.]KC5Z
MZF`*'SX1QOZ=?-W8?A'^?^Z>U;',NK;8YOF+GV>A;_J.&]TA"Q?;(,0NU6OS
M=_'$1Y`=1^Q<_P!O3[\0C^A<FG\!N9NQ>M;=YJ;<J;;Q\QCEWD2EG_/;NC69
MY188=.J[-L]<NP+)1H/W$>[`AS`96H+J?'D(!]#?4H=G[E\`L.[7&XXP-OW2
MZVRY].A'IB9_EY"0!Y6TJZU'2Y48F-[]*]LTW"`?!(R-XY5\I_?_`/5B03^2
MLZ=,_5%JB[1VZ9+!J6#%_(9N5VBY4SZC`%5`J[=1-4H&3$0'L/R'7,/I)1).
M]5DKJ&7Y*\R(!'_QW\#C!X\`=S4'^RWY'$37!^CX,/MMXLSGITGN1%GXM0.?
MVQGSDMSB8V&7X]K/PJ,ZI7(=Q9=43*6>LCV2D6IOP@`Z2#Q-LJQ*F8KLQ>V]
MQ-QY*.R&\VW?B+:H>92W49VB(+:K>A?502,([;X(PJMY\B5+K(2"@,I>/-_*
MY5W81BY+#TQY=745R7PRZ^RM>HQ,W_(=T&0I'JOVZ$A5G:,_KEMQS((/]O55
M1?KN[9J%8=/&K,Z"B2OWNH6&=$\2F#R*80_01ZX#]+6V1;AWFVZYN`IM;&"Z
MN7U4H!';R`$UJ*!W4XB-B16W)&?X5#']A`_:1B&WB][!;GQ)]+W/;C9=)UTK
MRDX4ZO>N'F>L#NC+V)_+[A9YJOYJ\BNSMT\=O:Q.N;*HB0#J?4V@B$`P@4.N
M]<R[8;?S?O\`\:Y;M\:CAO(;*'=)S2D86TC1YPV0`$B"W!-!5IB:8EKJQ2YW
M>"X0?]-,H<^SR@5'W^7[SAW?\9-I<LAKOL$X>:',+R=QXX\EX`)8CIS(+';O
M+/2_\;E4T"2BAW:2"4KFR@&*/P"@B/SY`(Z/]7LEAOMUQCG>UQA+#==H?30*
M*B.7U%)TY5TSC[OLQB\B*2M!=1BB/'E]QK^_#H?Y!VV6B$XJYEP^RQX\3V?V
M`[I0..U5:Q0N`ETZ>ZL,,^O\FU_#,#HK<P+1T6X$H?\`<2Q_]`'K3?I?X]9W
M',[SG>\JIV#C&VS7TA:FGU0C"%37*N4DB_ZT0QC;%"K7+74O\&!"Q^WP_>?N
MPG7\>W1;GG-4Y<^M38IIQ):KP+Y`VJ"A'$BY<J.9[([[,RLI7IN+(^,9XK"K
MV)G(/4#"(E392[,H=@$O>6^J':MOW:]V/NWL,839>2[7&[A0*)<PHJNC4R#A
M"B'VO%(<7-]C21HMQB%(IXP3[F`S'X4^\''A^[7<]"U#E/P$]4^8Z[;<3C^6
MUR&R\@+WGSY[$7A'*V,FM'P59@YF/=M%F:5G<0$Z+A,WDDNJS;%6`S?[DE<G
MZ>N.;7L_#.3=Z=XL8-PEV.W].RAF`:$W!4,\CJP()C#PZ3U`9]-&TLM6SP1Q
MVT^YRH',0HH/2M,R?LJ,2,<.O4AQ!X+:JZV7`VNLM+Q*YS)YI/N;OKEOO\=8
M(J7G*W87LS(Q=F=O6K>R'D:P@)5V8-42IJ*E!'L</'E//.^'.NX^RKL')FLF
MVY+I9T$5M%"R,B2(%5HP"4TR-D^HDA3JRQ'W6YW5Y%Z,^G0&!%!2E`1^_P`<
M_?B![^1U,XM$<^/6:IR7+>WO'/\`Q;8%-BA<[?61I:I6K%FZL0$89.JR<3,J
MO@DSMA_X=9-4$@/V-V[@/TG]*-OR"?MIRX<1^67E7K6WRKSA#&LFB3-O45DI
MIU?$"*TRQ-[`)C8W)MZ?,5736E*T/MJ,2^>E$GKVD\-URW^NVM[+6\YE=:)`
MWU':I#0'<\ZO%<I]>>)K12.@6&Q/D8DD!8VQ?)NHFDHL!P$OD3OUPKZ@CW0B
MY'8V/=.6PEW5++7";180@A>5Q1O11!JUQMD02!0]#B)W?YX3*M^5,FFHTTZ$
MT\`/9^_QPW/A4[>*?R#_`&UM%'CM5HWP_C8=NT4=+J-6YU*I0_,R#8ZAD$3'
M']1*4.XB/]1ZVON#'&/I?X1(%42'<;^IH*G]6?J>IQ?NP/Y+;'QU-^;83O(7
MKTW\ICE2Q,]>F8I\%:LJFQ,[<&9)JC$\?^ZI&8J"V(J/D/\`<!0'Y'Y^1ZE=
M]CC'T:[-(%7U#R205H*TU7OCUQ>F`_RS$?'US_OXN_Y#?`?C?)\2N5//M>#N
MB')BFT/,8RO6N.TR]QM?:-66@4^GMP5HS*=1J3HX0,\Y3,91H)C'."@CYE`>
MK?TN=R^60\WV;MFLEN>(W%Q<,\;6\+.28)9328H9!YT4Y-T%.F*-COKA+E+,
M$>@2U00#X$]?MP_KU1^O[C1Q2Q?/-LQJNV^*T'D%Q]Q25TV2L>D7FZ,Y5Z[J
MD=;%U8Z)M$Y*1L%YS<ZY4[,TD2@4X$`/`H`',^]7<[EW->077']_E@?:]KW2
M[6W6."&(J!(T8#-&BL_D11YB>E>N,/<[ZXNIVBF(*([`4`%,Z>&&B<4WCQ3^
M1G[.6:CQVHS0XH\>E$&9W2YVB"AX7)?-1%J904$CG[CW$I0$>X_U'K>>:1QC
MZ5>(2!5$AWJ]!-!4^>ZZGKC(N0/Y';GQUM^;X33W-7?6>3?//@GZC:GI=FQG
M'^1L7*ZUOMPHT@O$W*UU2N+7)5O2&,F@14$&"4=G\BM^.J11FZD73-1R11)K
M]9YCL%MVR<0[:\D[XWUI#?[[M+K;644RAHHY'$592II4ZIXQJ!#*BR!""]1?
MVB.*WL9]T=0\L9TJ#T!-,_VC[J^W$E7"3U"</O7_`*3):OQ_;:J6XS.;K9E,
M.;]ITU>&$A%NY^'L4A.#&2:96<?99![!-2*JLRMFP()B0B!/,XFY'W"[Y\[[
MG;2FR\G-E\A'=BX40VZ0LK!&14U*:M&H=B`VIJFI8T%(V\W2ZOD].?3I#5R%
M/;E^T^_WY##./Y"FM7!_@>!\#,ADUF>R^PGD!1L;C/PE5DW<=G<-88*5N\TN
M9FH1ZWC$I9W#MG9RB4#,%W0=^Q3=;[]+NR6$7)MS[E;Z@;8.+[9-=-4"C3LC
MK"@KD6TB5E']L)[1C,V&)1.][*/TH(RWWD&G[*X1;^.#K-TH$-S%]:>S2B[C
M5.%NZV@\&21=.EW4C0+1/247*+1GYBBJQX1G=X5>11-Y"'XUB;=A$IBCUL'U
M7[)M^YS[#W<V!`-EY!ML>O2``LT:*RAJ9:S"X0C^U`_L.+W((D<Q;A"/TID'
MXC_P-/NQ[WO<>/6O,;T9IM7KQJFZYR`DZ3:NW#9-TE_EV%?[3DB*A"N$^QA#
MQ.!@["(?ZCUC?3='&_`NXQ=58KQRHJ`:'TKSI7I]V*=E`-I>U\(?W/C934\_
MK4^KM]O@?Z_+_P!GS\1\._\`V>7Z]?)0I45Z8U['SRN.%1X,2/+;<<U]^%9Y
M#U;F+;=]EY*EZ[I5YO=;Q=M`*.T5HN+;3]:FF+2%@!F3@JRE>[JK_M3AD1)=
MFFB?[/U(Y9?=QHN$;=NWTT3;7-P.#;%66V@AADNBX!U,4D0EWT9/'Y;CU%D)
M60L*;Y</>_*I)LAC-H$%5`!:OV$9GW=:UZG'T+F*[-RR9N8]P@[8.&K==B[;
M+D<MG3-5(BC9PW<IF.FX061,4Q#E,)3E$!`1`>ORYD61)&24%90Q!!%""#F"
M/`@]1X8T0UKGUQ==48\QA^AB(4"\B`B`A3[,("`B`@(0KT0$!#L("`]9VU_X
MG;_\^/\`]8Q7'_$7[1^>-?#^+0\>/O6/)K/GCQ\N')W8D_O>NG#Q;ZR1=$\2
M?<Y454\"]_@._;Y'^O7U#]94<<?=]%C557^3VN0``^*;P&)WDH`W*@_^V/S.
M-=[FQKO)#CA[PN:O,/"&5AL;'A_K.::'JD(SEG@11\JM].S;/[#%3D85QX#6
M+.$\,6Z<$3,$>L^1<F\?K^PGU-V]V/B?*_IVX]P3DC112;[97$%NY4:OF8I9
MYD9&I_$CT>HJDC6$9,ZT,]90V]QLT5K-0&92!_M`DBGO%*^^F)^L&WNB<EO?
MMF&W9):1LF7ZGZD(VY5I9M(?:W3!_KYP=Q\I'MW2S6/LT"]*JQD&QP!PT=H*
M(J=C$$.OF3DO&MRXC],]YQW?(?2WBRYPT4@*T/EM<F5B`6C<4=&'E92&&1Q"
M3P/;[&T,HI*MT0?_`"_D?#'?[Y=_V"S[=P(]8^.Z;+XXWYM:9'-M?T.IR,A%
MW./H#>[5:NQL-$2$>1!U'M)1X\?N5Q1<%.Z/')ME0!LJL"E/TV<8V*SX]R;N
M_OMFE^W'K-C:P2*K1-,89'9V5JABH"**KY0Y=?.JT\V2")8)]QE4.85\H/2M
M"?Z/Q]N'X\0?2MPNX2['5=XQM3:WND56IVBIDD]!UN;ND=-$MQ2H2LY+PCYL
MC%ISQ&(&;HJ,4F3<B1S"9$R@^?7-N=?4#S_N%L,W&]__`)>NTS31R:8+9(F3
MT\U17!+:*^8AR[5&3`98P+K=KN\C,4VG03T`I^_\ZGV&F);NN(8C,:ZOHE]4
M=BX98K>%N8O'K$0Y#FW![:\_O7XE"TZVP5)1IM18PQ82](L'TA6Q:6%O*'(W
M;K(G(98RG_Q`Z^J/J0[U6O/N06R\#W3<?\K?RX1S0UFMXGF,LI?7"6"R50Q@
MLP((`'AB?WO<UNYE^4D?T-%",P":GJ/'*F)D.:69V[:.(/*#(<_9M)&\Z?@6
MM4&GL'S]O%,GMFME&FX.$:NY-V(-8]LO(O4RG64$")E$3&^`ZX-V_P!WL>/\
MZV??=S9DVZSW.VFE8*6(CCF1W(49L0H-`,STQ$V<B0W<4LGP*ZD_8#GC60Q3
MT\\]N%^;<`.4G$NMTJ%YO8XRM.:<QL.7TV&AL[Y!Y)*:3=;#"EF;6@<:W(S;
M.IO63!50XG4(;\!TEV<Q105^O>0]]^VG/]VY/PWF\MQ)V\OVCN-KNQ;N\]E<
MK!$CZ(S^HJ&0.X`H#^HC>28Z=BFW:RO'GMKLDVCT*-0DHU`#0=:5K3[QT.-B
MSG9Q'B?8%PNT_C7=3+9_*:A4H9]$OW'X4VXSW1(-Y&6NL.GG[<X682Z$%9HU
M)!Z#94R;IK]Q4E/[RG#Y7[;\XG[8=P+/ENWTNH;.=PRBJ">!PT<@&H`J7C8E
M-0JK:=0R(Q`65T;&\6X3S!2?O!R/[.F($LTA?Y'N3<7(W@3`<9^.DFC6ZBKB
MM.Y?R&TP2[B`S0C-Y78V=-!'M!)20F8"O'23C7BL,1TBW;H_?&N'(&$WTKN]
MQ]*.]\R?N7<[ONJ-+.+N7;%M'`>XJ'9-?IZ51WJ9%$I4LS:952E)R0\?ENC?
M&205.HII.9ZTZ>)ZY_?3$X_K%X&5?UR<0J!QOA99M:;.S6D+CJEX;-56B-UT
MZS`V/8I=J@X,9TG$1[=HVC(X%>RW[<P0%4`5$_7SKW@[E7G=;G5URRX0PV;!
M8K>$D$Q6\=="DC+4Q+224R]1VIE3$-N5\VX737#"B]%'L`Z?TGWG'SD_9:W!
MI[%.=#;N<13Y7;B<?L+XG`75\F'@>1?@0`2N`$H_^\40'_7K[#X(VKA.T-__
M`#H/V1J/W8AV^(_;AN.)))&V3,#"DF)O\W@/[A(43?\`SJ?^HAWZVIF8*:$]
M,0_(/\#N_P"[O^6)O@*4OP4`*`_T``_]76,23UQP2@Q-MZ+?_,5LG_9BJ'?X
M^`\KS`^/<?T#R\1[?U[#_0>N!_4'_P!L6/\`?S_[3XW_`+>?XI/_`'?_`'UP
M\OF/ZZK+RH]KG"[?[]D.;ZSQ'RC"=:I>MQ>AK5F<9#;YQO<'M')_R^G4W*MA
M3:S[Z/7(L5$Z;=4OF(@*?6H<"[JVG#.RV_\`&-LOKNRYO>[E;2VS0"1#Z:&(
M2_K)0)5`X()!89>..Z6M_P#+;=+!&[+<,P(I4>*^(]VKQ_/$RU-I%+SFN1U.
MSVH5>B5&'(JG$U:FP$36*Y%D764<K$CH2$:,8QD19PJ=0P))%`QS"8?D1'K@
M=_N.X;K=O?[I/-<WTE-4DKM)(U!0:G<EC0``5/3$4[O(Q>0EG/B34_CB&3..
M#6_07O5Y'<Y;#5*T;C;HW&&K9C5+$:S0CZ==7**B,?:.FKBG^1Y=@W(O49`H
M.#D`@E3+V$04#KON[=QN,W/TX[5VYM9YO\V6F\27$B>FX01,UT01+\)-)4\H
M-<S[,2\E["=FCLE)]=9"2*'I5O'IXC%S?N#^]S'O2P/G)`U2MDXW4'BE9<JL
MMB)981E.-KM*(ZD1LT0J`&)+O6QQL[$!<D(*8`<W<0^L>J=L[B<:@^G'<^W5
MS-*>67.]1W,:>FY0Q*;>I,OP@_IOY2:Y#VX\2]A&S/9$GUVDU#KT\OCT\#X_
MGC$?;QZ^^1WLKW'AQAL<Z6S_`(7T&8N&I[UK$):ZXA<T;R6(>Q%&AJG3I%1U
M(/9B,:I+D0?G9JLVQILRIO(S<2#F]C.Y_%.TG'=^Y'*HNN?W4<5O9VSQR&(P
MZ@TSR2K10K$@L@<,WHA1D]15M5_!MT4LQ&JZ8`*#6E*BM?<?'.N7OPRC3?1[
MR<XS<GN'7,+B!R`W3EYI60:['ET^*Y3[%7E)=#%G"+M&Q0U0M$JTC%`9RT5,
M2S)Q'G64**DB19,A1*J)NA;1]1/$.7</W[@G.=KVW8]HO[$_+MMUJ^DW0(*/
M+&I;-66-U>@RC*DYBF8F\P7%M+:7,<<4;KEH!&?M(%<Q0$=/MQ*Y[K.*&V<T
M^`UZP7CY!P]BTV;OV36",BYZQ1=7CE8ZI7R(GYE167ESD8I'1CV9S%(8>Z@A
MX@`B/;KBOT^\UX]V_P"YEMR7E$DD6T1VURC,B-(VJ6%D6BKYC5B,_#$9M%U%
M9WJSS&D8!'CXBGAAG.6^O;EQZ]_8BUUK@W!PMKX%\DP:O.3G&ES?HFHL<>O+
MPS!E+W[+(2P.DHM\:/6*609)-3$6.R!Y%'`J/[<HEOF\]T>#]T>UAV3N+))#
MW*VFHV^_$+2FZA&HK#<.@+#4/(Y;(/Z<XJWJALN6_MK^Q]*\-+V/X7H26'@#
M0>/0]/`^W#I?;[Q)WKF;`<+LPR.M14[0ZCS7R#8=_?2EGA(`(3+Z`:2!^Y:,
MI9VW<V%TH6:5,5HT(JL8R0!X_(#UIO8SF_&N`W/(-XWR5X]RGX_<VMD%C=]=
MQ-IT@E00@\@JS$#/KEC%VNYAM6EDE-',15>O4YCI[P.N(Y^3WI1V72/<;0N2
MU`:P!>%>D:9C7(;DO`JVIA&"KKF*HV`[5!6D*&!]9B69^U:K@Y2`Q$5IV1,?
MQ[B(]5X?]0>P;3V&N>([F9#W`M+2ZL;!_3+4MKLI4B;I'Z8+#2:$B&*E<2-O
MO$2;2;:3.[565#3^JU/'W?N&)!>*G"O;^/\`[:_83R/_`&*&0XP\L*%E-@KT
MTVLL6M,'UNILX1I86#ZIIJ?NK)%=Q(S3@KLY/J/W*`&[G[!R_FG<'CW)^R/%
M^)^I(>7[)<W*.AC8+\M*7*$24TD@+"ND&O7++$?<WD4^VP6__'B)_`U^[II\
M?;[,-3YT^K3DQ[&_9U6K[I-PNO'KB#QYP]*,P_6,>T.K,]9E-@E)6*G)^3@X
ML#RLQ3#+N))1LJ_5;(JF;U]$$CE_(`0W7MQWEXCVI[03;9M,%ONG.MTW'5=V
MUU!(;9;559$5V\J2T"A@@8C5,VH>7&79;G;[?MQCC59+J1_,K`TTYC/P/XGJ
M?9C'^-7J/Y+^O_VAY;R'PW3='Y-\?]5RRTYURPO&^:;6W6LQSAR*:M8?$,NV
MCG]UC(9_78%5L!2K.T$6[I$#@0R10RN7=\.(]SNSMYQ;D5G:;/R:RO8Y]MAL
M[>06S`92#(LL3.KS!LPI)1J5!./;G=8+[;FMYD6.96!0*#3]]*U-<QX8<'[A
M_7-R)Y'7[B]S5X0S]9C.8'#ZQ_F52KW)RTCJ[HM7=SD=,!$JR\DJ2(8O8-^B
MY$S=Y];62CI%XB9=%0$1-J_8CNMQ7BFV;SV^[B13/P7?8J221`L\$@1DU:5&
MHAU*^9:M&Z1L%8:J6=IW""W22SO`3:2C,CJ#2G^GL(&%YX2[=[=M+UH8SFSP
MUP'CUB[&D2J;NTT?7$+M<YG2FCR+",5AH6.M]E;,J9)LE'?DBX*=PB<B8@Z4
M#N0=:[A<>[';1LGK=O=^W/=-_:X6D<UL8HE@(;4&9HHR95.G-2%(J-`ZC&O(
M=LCCK9RN\E?$4R_\HS]]?N]C5O;!P[YLZOSEX`<NN(^09[L9.)[+1)"P5?0=
M-A<ZC9.9L+R)3BHU5>1!5ZJU59E75,J@DH!#I%`P?/6Y]E.>=OMD[<\GX-S>
M^NK`[VT"I)#;O.RJ@;4U%RK6@H2*@XRMLN[2*RGM;EBOJTH0">GW8E`X87?F
M==JS=W',SCEE7'*Q1]@CT*1"95J3;48ZRP*T8562EI5ZV9,BQ+UK)`")$A`1
M43#R_0`[\>Y]MW`=ON[=>!;K>;K:M$QE>XMS;M&X;RJH).H%<R?`XC+E;96'
MR[EU]X(_,#W^W[<Z")3D1QA]CG$OV;;3["."V,Y]ROHG)G(:72-7QRVZ;#YE
M9ZY9*8C7(AC)03^:,P9/&:;.L-UVZA%7*G_'/4E4"@1!;KM_%N8=J>;]H=O[
M7=Q[^ZV3<MHOI9K:ZBMVN(WCE,CE75-1!)D96!"CR1LK&K+B6M[C;[K;TL;U
MVB>-B0P!((-3^_W=!GA2O7+POY?RO.OD9[0N=](SS%M<U_-JYB^<X-G5L"ZI
M4RD0[6G_`)T[:++'OG\0^EI%*GL4$TR+K'!4'2AB-RF02"([K<_X+!VWVKL[
MVWN+K<-CL;M[J>\GC](RS,9:)'&RJP5?5<DE0*:`"YU'%N_O+864>VV;,\*,
M6+$4J<^G3V^SV=</1]N?'#5N7'KLY*<=\0B(R=U+2H&G,*G$S$XPKD:[<0^E
M4NR/RN9J4.FP8@G$0S@Y14,`'.4"`/<P=<_['\KV7@_=/:>4\A=X]GM))3(R
MHSL`UO+&M%6K&K.HR&0S\,86VSI;7B3R?`M?VJ0.E?'W8=OQMI=@S?CK@>=V
MQL@SM5"Q;+*79FC5TD_:M;!5J-!0<RV;/D!%!X@A(L5"D5)_8H4`,'P/6D<L
MW"UW;E6Y[K8DM97.X7$L9(()229W0D',$J14',=,8]PZR7#R)\+.Q'V$DXC=
MP+AWN]!]R_.+F59:_"M<%W#`L?H.=V!O9HIY-R5EI\9GK:<:OZPBH,K$MT%Z
M^[`BRQ034`A1*(^8=NL<FYYQO<^PG'>!6DLAY+MVYW,TZ&-@BQRM.4(D/E8D
M.N0-14UZ8SI[J)]KAM5/ZJ,2?O+?=XCQ_+"">WSUP\I]MW_B[[`^"%AK'_5'
MQ4%M%-LYNTF2#@=`JC2P2%A:M64T[<-HI!U]DY)L)%B\5:(2<7)*%!T@JBF"
MFS=C.Z_#./<8WGMAW)BF_P`F[U5C/$NMX9"BH24`+$>2-T=0QCDC!T,K&F3M
M6X6T,$EC>@_+2^(\#T^WWBG0CI[';\$ML]J^IWN6:<Z>'6)\;\UCZ,]4CK#1
M-::7>U6#2"3<(5BV1KL?9;,A#U-2NK/S*BLNHN5VBEXJF(8Q0T;N1Q[LOLVW
M(_;C?MPW;=FN1J2:V,4:0:'U$NT<9:0.$I0`:2U0"`<8E[#ML2_]'*TCU\10
M4S]PSK3\<1W\S_5/RH]B?M.+K>HWBY\;>)6#8S'U7`M1QW0ZRUV*9O#A1"5G
MWT"R:*R<G1ADIJR2";IZY037581#9(G;[^Z?5.`=Z>&=J^S/\CV:VM]VYON5
M^TE[;W4$AM4A%517)"K-I2-"J*2`\KL?ASD+/<[;;]M]*-5DNG>K!@=-/?[<
M@/O)]F,,X^>GWE1P"]J^0<D>/V@7GDOQ[O\`09FE\I;[NVG5G_FVD:RG=L5U
M7)54HY_>6->7@*W+-#@FHZ[LUVW<0^OOG\H[[<,[F]E[[B?)[6VVCE%M<K+M
MT-G;R?+?IT(I34L+.'GC85"^=7]N*KC=K>^VUK>=5CF5JH%!IE^(%:D'IUKA
MUWN@X><N^2&F>NW7^).;4S4)[B-NUAV.R5J[:%$YY&/S,WF:2];BCR,B8'"K
M:8>5)PBN=L4RK<G8W;^X.M*[`\\X-Q/9^5;%S>[N+.VWS;4M8Y(H&G9:BX61
MM*Y`J)5(#4!^[&-M-W:V\5Q%<L5$J!00"?!J]*^T8D4X;:'S?T&%O;CFQQUR
M_CU-QDO#(4".S'6TM8:V>'<,72DT_EG:3-H$,XCWQ$4TDQ`16*H8WQX_/*N>
M;7V\VNXME[?[K>;I;NC&9KBV-L8V!&@*"3J#"I)\*#VY1UREJA'RSEQXU!'L
MIU`]_M^W.@@9]@F%>X#V=UJ6X@:1P,XP9+G!M>*X@>7,OK5;M4M3Z!!7`RK:
MT5*J-9J;M\+-VNK-FR;YLW!11TB==LHFB53S0^E>U_).Q?9^[3G6U<EWB]W;
MY&C[8MM)&LLSQ4,<LA1(G2.0L49J!2%<%J4:<V^?:]N;YM)I&DTG],`T)(\3
M0#^@^)\9L.4EOMO`;UH:79\??5B=MO%+B\U9T23U)0&T#,.,OIT;!1S^QHM)
M"*_+?OVL9]B;)%RB+U\9-N0P"H'7SWPVQL>Y?=RTL]]6:.QWK>"9EM\W47$K
M.RQDJU%4M0N5.A*N1EB'MU2]W%1-4)+)G3PJ:_Z'P&>,Y]>.U;/R,X3\<-QY
M"4MG0-@TW.6-HN%:CXQ]"L2&>/GY(*<9PTF[?OXEM;JTBRER-E5CF0*^`G?L
M4`".[I<?V#BO<+=N.\7N&NMBL[LQQ2,P<Y!=:%E`#&*0O$6`%=%?'%-_##;W
MDD,#:HE:@/YC[CE]V'57".=S%1M,2P(51]*5R;CF:9SE2(=V^C'39N0ZI_[4
MRF65`!,/P`?/6EV$J07T,\F4:2HQ^P,"?V8Q4(#@GH",1!>B#ACOO!+@\]P_
MDA7H.LZ(ON.C7A.-K]HB;<P&O61A5$(MR,M#**LP756BEP,EW\R`4!$`\@Z[
MI]27/^,]R.XB\BXG+)-M8VZ"'4\;1'7&TA8:7H:489]/PQ*[U>0WM[ZT!JF@
M#H1T)]N$=X]>MK76'M5]H>][UGM2F.)_,C)&>:UPBUHAIAW<(Q]'4")L41-U
M9HL,O#-G+"&?$^Q8$Q`2E$@]S%'J>Y1W9V.7LOP[C/&KJ>/FNPWQN'I&ZB)@
MT[(R2$:6(9TR%?&O0XNS;BAVVW@A8BYA>OCEU]U/VG#/O4EZ9.4OKU]F6I:3
M9DX.Q\5(S--8SO'M`_SB*?6>4A+/=:=9:@VEJ253]TA9$L:P<EDC@0K<\@DJ
MJ7N58IC;WWO[^\-[H]HK/:;0R1<T>\MI[J'T6$:O'%+'*5E^%EU%?3%=6@J#
MFI`R]TW>VO\`;EB7*YU*6%,L@0<_MZ>[#X_=+ZSMRYC.N-W)CAY:JY4>7'$:
MVJV*BDL3XT$TN,,K,0-C:1:%E%%TSBIFM66O).F9'B0,72+IV@LJD"A3=<Z^
MG_N[QS@:;MQ'G<,L_!]\@T3:%UF)@KQEC'4%DDC<JQ4ZU*HRJU",8>S[C#:>
MI;78)M910TSID1T]A!S^["K<)^0/N+TW98*L\SN#F'\?\7CJC/C<](JNN1MJ
ML,Q=DV[=2KA4*Q&7BS'90KM<BR;Q)P5T)`.4Y71/#ZU87N%QCL/M&PR7?`.1
M;CNF_O.GI026S1HL53ZGJR-#'5P*%2I6M*:#6JV;R#:HXRUG,TDA.0((H/?Y
M1^8^PUR77D[>?8U`<M>(U9XPY%E=RXDV2;43Y8WNU2S%K=:9#C,M$7*M<:/+
MC`KD_#K0JNF@M(^64=O@^A0B1`*)];X?MW:JZX1OEWS"^O;?F\,?_P"MAC4F
M*5M!(#D1.,Y**VIXPJ>8%C6EFW2P:UE:X9A<@>0#H?V'QZYB@Q(KURO&!@Z8
M8.F&#IA@Z88.F&(-_;1Z5<E]A4$^U#.?V3)N6T+&?7#Z`5H9"MZ<U8HB#"I:
MVT8)'6>ID*4$F,XDFI)1I1`I@<MB@V#K7;CNIN7"YAM]]KN>-NWFCKYHB>KP
MD]/:T9.EO]5O-BAD#=.N-"4V&:WQLY9UG%]RHLUG6ETW0H!M-UN;1*!C(J/2
MF8S$._1%2/GZY,(%^YE(LU%6CI$?(AQ["`?:&U[OMN^[:FZ;3,D]A*M59?VJ
MPZJR]&5J$'J,0/(`1LEV#U]!_P`L;$/$3A;KG,.XFAZ0T_8J/#.D27?3I=JL
M>NUM$WB<[%D0#(C8+0NB/="/0.`AW`ZYT4O[^M2YKSO9>$6/KW[>IN#@^E`I
M&MS[3UT1@]7(]RAFRQQ_9-AO=\G].W&FW4^>0_"ON']IO8H^\@8V].,_%G(^
M*5!0HN6P94%''TN+1;9(J+FV7.633\#2=@E"))F5`G<0;M4P3:-"")44R]S"
M;XJY7R_>N8[B=PW>2H%1'&M1'$O]E%_-C5F.;$Y8[;M.SV6S6PM[-<S\3'XF
M/M8_D.@\!AQO6KXE,'3#!TPP=,,'3#!TPP=,,'3#!TPP=,,'3#!TPP=,,'3#
M!TPP=,,'3#!TPP=,,'3#!TPP=,,'3#!TPP=,,'3#!TPP=,,'3#"=ZKDF8[G1
M)O,-CH55TS/+)^!^^TRZ0S*?KLJ,7(M)>-.\C'Z2S=51A*,47")A#R362*8H
M@(`/4KLN^;QQS<H]XV&YFL]TBU:)8F*.NI2K49:$:E)4^T$@XN12R0N)(6*R
M#H1D<*`DDD@DFBBFFBBBF1)))(A4TDDDR@1---,@`4B9"@```````=19)8EF
M)+$YG%O'9UYA@Z88.F&#IA@Z88.F&#IA@Z88.F&#IA@Z88.F&#IA@Z889)S$
M]?'&7G(C0'.WU!PI;<OL<98*+HM4=HP%^@$F<B@_DJVC/@T=F=56Q$2,D\8.
M$UD>Y_O1!)R1-8FX<2YUR'A4\DNRRCT95(>)QJB8THK%:CSKU#`@^!JI(.+>
M6D5]:R6D]?2D4J:9&AZT.'39YG-'R>GPE`SFLQ50I]=:E9Q,%#MP;M&Z8?W*
M*J&$3+NWKI0147<+'4775,8ZAS',(CKVY[IN&\WTFY;I*\][*:L[&I/N]@`Z
M`"@`R``Q5:VMO90+;6J*D"B@`_TS/M)S/CC->L#&1@Z88.F&#IA@Z88.F&#I
MAA$S<DN/Q<^O&L?\Y\T4S/-++.TW0;XC<8->JTRVUB:0KEAK5DFD'BC&)G8>
M><I,W#58Y5DW"I""7R,4!V$<3Y.=TMMD_E]V-WNX4E@A,3B26*1"Z21H15D9
M`65@*%036@.+WR\_J+%H;U&`(%,R#F",>?4N5'&V^0D#8Z;NF666"L^A-LE@
M).(NL$\:R>H/8YS+L<];G3>"/^9/XIH=RA'&`KI=``4(0Q3%$;M]PSENVW$M
MI?[;>PW,-J;EU:)P5MPP4SG+^$&(4O\`"#D2"#CUK:X0E71@P74<C\/M^SWX
MRZT;3D-(CM&E[CIM%JT3D$;'3&J2=@L\/$Q^=1<PR-)13ZYO7SM!M7&\A'%^
M]$SHR7V(F*<.Y3%$<&SX_ONXRVD%A9W,TU\[+;*D;,T[*=+"(`$N5;(Z:T-1
MU!Q0L,KE0BL2Y\M!U^SVX]U?0Z&VN<!G3BY5E"^VJMS5QK%.5FXY.RV&J5QW
M#,)^QPD.9P#Z4AH5Y86";IPB0Z2!WB('$/L+WQEVO<GL)=U6WF.VPRI%)*$;
MTTDD#%$=J45W".54D$A6IT.//3<H9`#H!H3X`GH/V82>^\N.,&74NGZ)H6^9
M54:1H+=1Y1K--72%:Q5N8H($=.I&NKBZ,,O&,6RI%'#E`#H-R'*94Y`,41F]
MMX/S'>-PGVK:]LO9]QM32:-(G+1$F@5Q3RL34*IH6(-`:'%U+2YE<QQHQ=>H
M`Z?;C,)[><3J\/.V&QZUG<)7ZQ6:7=+%/2=P@F<+"4_1I)]#T*U2<JL^(P9U
MVXRD6Y0C7IU`;O%$#@F<WB/;`MN-<AO)X[6TL;J2ZFFEB1%B<N\L"JTT:J!J
M+Q*RF1`-2@BH%<4+!,Q"JK%B2`*'J.H^T>./8L.L9C4D[NM:=!IU<1S6NQ-N
MT):<L47%HTJKSPS)82P6=9ZY13A8B7-7GP-EUQ(FL9HJ!!$2&`+%KLF\7QMU
ML[6>5KN5HH`B,QED31K2,`'6RZTU!:D:EKUQXL4C:=*DZC09=2/`?CCR,EW?
M&-XBI6:QC4:-I\9`R)8B=<TJR1D\,'**-R.TH^:08.%7$2\7:*%633<$3,HD
M8#E`2B`]7][XWO\`QJ9+??[.YLYI4U()8V36M:%D)`#`'(E2:'(YX]E@F@(6
M964GVBF,<KW*?C?:]1D<2K>XYA-:Y$R<]"2&<Q]QA5[<WFZL116RPO[,5U^6
MK,0"**BCQJ0IEVZ:2ASD*5,XER[KAG+++9DY#=[=>1[&Z(ZSM$XB*291OKI3
M2Y("L<F)`!J16IK:X6(3,C"(@&M,J'I^.//IG+SBYHE^7RRC;_DUIT9N[L4>
M>E0UW@GEC4D*BNZ;6B/:1B;S\A\_KRS%<'B*(**MP05,<H%3.);NX<&YEM6V
M#>=QVR^AVDJC>J\+B/3*`8V+4H`X(TDT#5%,R,>O:7,:>J\;"/+,@TSZ?CA3
MHK4\WG$<^<0UZJLHAK$8O-9DJQFX]RG?HAK#IV%Q)5(R2Y@G62$$L1X91O\`
M84K<P*"/B/?J'FV;=K9KI9[:9&LG"7`*,/18MH"RY>0EP5`:GFRZXM&*1=55
M(T]<NGAG[,\)]0>57&G5;K+YQFN\Y-?+W!)RRTI5*I>Z[.33=&`=DCYY4K./
M?KJ.4H-^H5%Z9+[`:*F`BHD,(!U)[GPOEVR[?'NV[[;?6VVR%0LDD+HA+C4@
MJRBA<9I6FH9K48N/;7$2"21'5#XD$#/ICT,JY*\?-SEK)!8UM.9:A,U#Q-98
MRBW."LKV(1.]=1J;QTA%/7*G[>K(,5D".2@9`ZJ1B`<3`(=6MZXERCCD$5SO
M^WWEG;S_`,-IHGC#&@:@+`>;20=/6A!I3'DMO/"`TR,JGI4$8QF3YC\58;5D
ML+EN0.4QVR+SC&M(9B[N,2A=EYV26CVS&,1KQW`2*KERXE6R90*00\W"91$!
M.4!S(>!<TN-E/(X-KO7V$1F0W`B8Q!%#$L7II``5CUZ*3X'%0M+IHO6$;>C2
MM:94^W"JLM6S22C:I,Q]\J;V)O=@DZI2Y)M.QRS*TV:&;61Y+0,"Y(N*4I+1
MK2GRJBR"(F43)'.!,``D?M"R;+N\4L\$MM.L]M$LDJE&!CC<QA7<4JJL98P"
M<B77^T,6S%("5*FJBIRZ#+,_B/QPFF5<NN+VY6`:ICV^Y1I%F_;%YE*!J%U@
MYF5=1#8Z1'4HQ9-79UY"/:F73^U9`JB:8*$$P@!RB,OO7!N8\<M?G=]VR]M+
M36$+RQ.BACT5B116-#0&A-#3H<7);6YA75+&RK7J01@I/+OBSI5AM-3S[D/C
M=TLM*C9V:M,'6=#J\S)0\-5GAH^SS#AJQDEE#Q5<D"?0_<I@=%FL)2+&(8Q0
M%N/!N9[3:PWNZ;5?V]I<.B1O)!(BL\@U1J"5'FD7-%-"XS4$`X/:7,:AY(W5
M6I0D'QZ?CX855II%`?JTY!E<ZRZ6T*M2%RHJ:$RQ4/;JE%-81])V2O`58?W6
M$8,[+'JK.4?-)--ZB8Q@!0O>%?:=SC$[26\P6UF6*:J']*1BX6-\O*[&-P%.
M9*,/`XM&.05J#Y30^XYY'WY'"2TOF%Q4T92Z)4'D5C-R-G<!,6RZC6M$J\PG
M7:I7CKI3UH?JL9)9(*Y"JMS%=OB&.U;F[`HH43%[SFX<$YIM0MVW/:MPMQ=2
MK'%ZD$BZY'H4C4%0?4>OE0T9O`&AQ=>TN8].N-QJ-!4',GH/M]V%M;VZK.Y6
M'@VMAAW$Q8*Z\MT'%HR#91]+U:/<PS-]88YL5057<.T=6)@FHX(`ID.\1`1[
MJ%[ZZ]C>)#)<O%(((I1$[%319&#D(QZ!B$<A3F0K>PXLZ&`)(-`:'[?9^PX2
MC2^4O&W&K7"476=WR;.+E8F[9Y#UBYWRMUZ;=L'CXL6RD31\G(-W+6,>R1OQ
MT7*Q4T%5P,0AQ,4P!-[1PWEN_P!E)N6R;;?7=A$2&DBAD=`0-174JD%@OF*B
MI`S(H1B[';7$REXD=D'B`3A5V5NJ\E(6>)CI^)?RE+58M[;',WJ#E]7%Y.';
M6".1F&J)SK,%GT&]1=HE4*!E&ZI3E`2F`>H62QO(8H9Y8G6&X!,3$$"0*Q1B
MI.1HX*FG1@0<6BC``D&C=/?X?GC&HO8,JFVF?/X;1J5*LM7C'TUF;J/LD2\1
MO<-&0_\`D$G+54Z#I0)J,C(40<N7"'FD@F<@J&+YE`<J;8MZMWNHI[2X22R<
M)<!HV!A=FT*LE1Y&9_*JFA)!H#0XJ,4H+`JP*G/+IX9^S/&%YYRHXU:TK<TL
MQWK)+X.=1YIB\GJM^K4RWJT(5202-/3#IE(JMFD`"D4Y+^<)_P`3N@?_`'/[
M1[2.Z<,Y;LBV[;OME];"Z;3#ZD,B&1_*="@J"7\R^2FK,99XKDMKB*GJ(ZZN
ME0<S[/MQ9YWRXXN:U#W"PYGR%QN[P>?0X6.\RM=T2KR+&HUHS9P]3LUB<(R0
MIQ-:6:-%E$Y%82,E"(J"540(;M7NO!^9;'/!:[OM=_;W%U)HA62"13+)4#TT
M!7S2`D`H*N"149C'LEK<Q,%DC=68T%0<S[![_=BZI7*GC5HU%M^G4?>,GLN=
MY]Y?YW=8R]5Y2M4PH1R$L"MIESOTV<"@I%NDW!%'1DB*(G`Y1$OSU1N'#.6[
M5N4&S[CMM[#NMU_!B:%_4E\Q7]-=-7.H%2%J010YX\>UN(W$3HPD;H*&I^SV
MXO*+R9X]:;`1]HS[:,VN-?E;NWS2/E8"W0T@U<Z&[8EE&E(*9!T8Q;2[C#E<
MI,3`#A1N<JI2"0Q3#1N7$.4;/<M9[IM]W!=);FX97B92(`=)FS'\,-Y2_P`(
M8$$U%,>/;7$3:9$8,%KF/#I7[/?CP:US`XMW*]R&8U3?,ML6@Q3JU,9*HP]N
MBG\TQ>48LB:XMG+1NN<R2]8")=`^*(]VXMU`/V$A@#)N^"\RL-M7>+W;+R+:
MW6,K*T3!")M/I$$C,2:ET?VM0IUQ4UI<J@E9&$9IG3+/I^.%*K>O97<F%!E:
MEHM+LT9JE<>W#-9&"LD3*L;W58UK&/9"PU1VR=+(3D.Q:3+119PW,HFF5PF)
MA#R#J(N]BWFPDN8;VUN(9K*413J\;*89&+!4D!`*,2C`*U"=)ITQ;:*5"P92
M"IH:CH?8?9A):]S7XA6R'T:PUCDOB,_`Y#`_Y5ITS$Z/5GT92*L+F09EL]A?
M-Y)1LPKBCN)<IE?F-^(<Z!P!01#J;NNWW.;*>TM;S:-QBN;Z7T[=&@D#3244
M^F@*U,E&4Z/B`(RQ=:SND*JT;AG-!D<S[![_`'8QY]S[X>-<[OFI,=]H5FIV
M;$@`MKNFR*END&;VVO7$;4X=I"U]&0EY2:L\DU408M6R*JRYTS=@\2',7+C[
M9\\?=;;9I-LN8;^[U^D)5])2(@&D8NY552-2"[,0`"/$@8J%C=F18C&P=JTK
METZYGP'CBXS+FOBFL9?I.IU<UQ;L,HJ<C=[C5K#5G,#<4:PRB9J99S4,P?+D
MB;'$3S:NO4F+UB]<,5'C5=J=9-PW<))4;OV]Y#LF\VFS7GRYEO9UABD20/$9
M"R(4=@-4;(70NCHKA65PI1E+)+.:*58FI5C0$&HK[#[*5S!%?'#N.M'QB8.F
M&#IA@Z88.F&#IA@Z88.F&#IA@Z88.F&#IA@Z88.F&#IAA,]G?Z-&9)I;_'X)
MO9M6;T>S&S>">/X^,8R%X/$.DZNG(R$HNW8M8U.9.BHY.<W<$"'\2F/XE&7X
M_%M4V^6D6^RF'93<Q^NX5F*PZAZFE5!);14*!XD5H*G%R$1F51,:1:A4^[QQ
MK+9;`3.8<?-EAL8T:G<HN/2]"X3/;+=,^SJ>Q"7B^4.>[OC2"5?M]:TZYRJ\
MYKV]9S.1[B<D3JQYXB2A&R4XVBQ<HG4^O-YN;?>.3V%QO]I/LW*!<[L(XIYT
MNU;;I[.Z.N*2WB4):V<Z.L*`/ZL<KM;/-H8#8Y&62X0RJ8I]4E`2&\A5LP0,
ME5JT&=03IK3#O]E&N:=?^;%HU!.2XV:V^KO`>KX_F\LHQO5GB=XK.PZ!/\5]
M-L\ECJ>A4).Z:/L$NT@&\4PFY&<95&',\E4V<8[0$NB[!\WL^V<>L]FT;MLB
MR[S)=3K6&-K.2UA3<;>-;KT)O2@M5:9I'B2%[F41P&29&KB1:HXX5BI)%64L
M>@TE0'`U4-`N=2`-1H*D8QS36-LL6#PT5IUAS#,!N/,)QIGLWM^IUZ1T_+L;
MO"T!3IS%.-ENJ:LS0W6AT!I_DF=02-C1?HU`\173/G#X479$ULO:)+*UY+)-
ML\5Y>>AL(M^/Q6[K;W%U"'E2[OXI=$P@F/IWTQ@*&Z]6<1K'J0E:HBJS$QAF
MI#2$*:,PJ0S@T-#DYI354TIEA.'=2D'UYX"TZRZTWA^3-7XU:3&<"MC/3+N$
MGI\Q5=$RR8RVU6//HAO/W"JYQJ7'INK%:5'3YT%8J-</SO%4E2,W?4JE]%'M
MW)K^TL3)Q";=X&WFU]6'3;K)!<+<1QSL4BDGM[TB2P>$$22+&(U92Z8N!P$G
M=4K;F0>JM1D"#J`.0)#YH1U-*>(PH/$"X6//Y'B?9ZWD3+>-%LOJPSZ+F,UK
M%MJM1L6;1T)IECE9"?A;'LTS1J19<QO%BGOVNP'BW;B?BE8"(7>1RK9^U.G%
M\ZL+7=(M[L[R^;;=JAYG.RW$D4DJ3L]O&JH\=JDTT=Q"B>I`)%6&033JDJO&
MX-NZ02"57;TT%R<Z$@D@9>4$U`%14`&IH00<6N\GH;O%.3#W1FV#0^9NN('J
MQ<Z%!YT^"3XZQ&?#RJVQS;XNJRJ4>WCI/)T:X=TV0<III(KLTSJ?6@D8H!<X
MT-R3D&T1[4=RDW==]Y$('G&F^:?^76@B:12Q9;DR:69220Q`JS`X0:Q-&(]9
M?U9J%OBKH6E??7"<1D'*5<FNIR5RKNGYM4[OZG;9Q;6U%G=JG9-5PD-IURTX
MQE.OGNM8;*U734EI%:KQ$Q9T&K)TO&Q#Z9.S5<+K%E9KB&\-B8K>6SW:>WY)
M'N(MS%+';7GREM'=W-MZ4A]2W(47$L5N6=1)/';B1453=+!M-`5D*SA]-"%;
M2H9EH<QXD#/,@5Q+#Q+=:O,\D>6EBT:)>U!C*Q6*&A*'H$AQDE-LK:HKZN_6
M+8G7'%*26#+4HN19,*F%HFY>84/'R:I3D14`RO%.;ILMOQ/9+7:G6>1'N]<T
M"[@MI(*6RC0+[2/F-2N]S\O#%$`\*D%A18NZ$0MXEC-2"U2->D_#TU_UO%M(
M`S&&61-FLDH_@L[D<W+7*0V]O&A6*-W^U6*I+P+NQQ/)ZX3[2A9E2ZW+3NP/
MM!MA@=P#I=U"14&PB3RCUU(#'I&^_H$]G:0QR;K%=^KN)X-`C64:2!Q&VWQ(
M9KB614M5@C\LRA99)GE$,:1>J1IS"J@&0-5_E`-(!K30!4DT6@Z]22:`"N,3
MR.HW"HSW`*_3&IWO5J+9N5O)2JU["IF)A:[1\WMMCE.2)XC5*+<(&B5E:>G,
MZJ\?.I*0EMF'YY.+DGBT:)WS-N@YS=\OK&^MN3;9!96UEN4.RV$CWBL[S3Q1
MK8:K::)YI`B3R-"1+;1((Y(T6:D<CLE<KHXG0*JN(D)85)(&BJD5-`33-0*$
M"N1.*,B?W*ST;UZ9_9X*3S2I4KC!R(@*-O4-)(6!AKT`''5*LU&^8]2:N,YJ
M<5).*.9.RN&%JB:T_9K$_!;)/70E*'N^1V%GN/*=TLY$N[VXWBQ>:S=2C6S_
M`#WJ2PW4TFBW91-6W5[:2=&!]1VC2IPF"*\\BG4QE4E>FDZJD,3Y>N55)]N0
MQ?9#)[I96'KU-$U:J9OC56Q:8C)1&V6/C%9./FD4^!XPZ'&M['QO=QL9(\NF
M,S>W+R+D95-PA`*1]2:ODG[8CD3$7M[Y#QRTDY2)YIKO?IMP5E,<>X1WL$K[
MA`Q2_#,NV%(0)$C(,P>Y:-HG*4*^3"%3<5):8OX!PP)<9/\`U,LP.M6I0TQG
M7K&EKE8[IF,[%U&\9MD3CBT]&O47=+#0[E*1[%:Q9P-;2X;61\W:<D7'%5C&
M)%!96X^3-P@K7?QTDG97'4;W@@L+3;[RVFGMKO?!O(US6:31*Q"3^H=UC!-@
M-Q+=!:T92+O42A7%O<@BHRDJTOJ9E01X&OJ#X-?^SG\7A3#IKJGW]MG'M7[T
M@$O`;E`3\80<?><IMVXQF,L40;BV^E,Q2@;R5*?R,7L40[B&F;>?_P#$-T6A
M_P"YMOSRI_\`#W#+K6OW4]^,=/\`"I/^>G_I?$?/'^FM(^-X)V8NK[[.+/.7
M?(<#9Y:6%C2P:)^^B<UA\Z4]<YA#QZTBS*GV:@$ZX#ZCN/#[>P"'4>37[RR\
MDL_DMLC5=BL?UXRAO&I-M/\`%`N&8*?ZWZ*YA*T\<Z=R3.NF,?I+F*:NL?7/
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M<M0/E&DM6I/0'&,+2E\T+(\#J>D58F`1M9]4_+:K06I/YXM^@M`2E<>PB#=Z
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MR_/D5D'`J@5Z8BKL_BFU[@0/D_/N:7[WO$MP5K+:K33R"#.R*$O^C?\`\;3<
M3T(_J9*,WZ^&'<OJMW\L:_K#X:9Y/US/W??A#.2<GI<9;?9E6<:JR=GLUG)G
MMGL6D05@XX0S;.T$>,E3@(S,N2D%RY9#77>".$8P9XTO6X^?9JLY24:^362:
M.DEMCXE#M$UEQ"\W^;T;2'UXT@=+YC.3N$CM<6#[8=8O06]'TIWA8/'"]'B=
M"MZW$92W:8T45`!#Y^<FJ%,]7A0D=`<P<.9XRW&^USD=OM01R:=O\9./^,P6
MW5\_G,HC<UIL@7C#F[5X=>$G[O5;B]BSBT*Y;?L,))(?B.D2D`#%433U'E]A
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MOUB_Z,GC*/!I9)A\V8J@U?LU`C4_J7,2/V7;X=BY?;W%A?W^]WC<D`,20SVZ
M+*4G`>9KQ88_YJ"VJ")&<:DD'K'4H-,2"*Y4H[ROZ_0`C.AS.J@]3V`>PYXQ
M'E3?X2ZW*V6[<<$H&/JT3UO\FCO,CUO1(6:#<L_FK5BKB683-SXUR.B(4?%*
M1,P31"(D9%9A-R<U.@,1'D_$?G+G\+VRYV^P@L>.;G=7ZW/+-OI<VT#I\G,D
M=V%98K]8#-=S*[&5$#PQQ0_KRG7$#7;1E$"0NSZKA/,H/E-&\'I5C7,"H`&9
MS&$VF7NA&S+1[1=X*]DK4!K?KQMM2S#F--YC_P!3-]LT3O#QU'Y3JUMSN-.:
MMXY:9#\=M1Y735"I-[6$@9\X0BC_`&)RT$>UC=[2SVZ2V^;EL=[BEN-K2X_E
M\,;68#7-M%.WZEU&NIKN/;Q5K?TA&K3"AN`1^HJH5U%903&#H`T_$H/5A_6"
M?U:4SP[[1+C8KYJ&>3%OR'/L.GV_.3BDT=5;_+:%;=ZE"(9OHZK.8W)3*IFY
MU2(_+;N`0JK4TL[<C$MCK+'1(LB@31=JL+7;=GNH+&^NMQMCQS<B)/2FBLUK
M/`"MI\RD4C4(K<L(U7U&"J&*LQQ(T5(F".SKZ+YT(7XA\.JA_P!K+KA(.&<C
M=$V6L185WF:M55K%SH21LLW*9P/$%K_^YMC>(NJO&E,UTL7?YZ?XC<OTK&"0
M47,)3-P!4L[SZ+;S)93>KL`O1%LY,:+/_,S_`-+:@B1L[>E/,V8\@45#>4W;
ML+5#6'72/(5U_"O7P_\`##"<'I,"ZX^9G'XMLJ<;Q8OWKCY@C"SL16M+4E<(
MY&-<4Q6O\CRY(W"F/G5XQJ7M0+SP#7VLD#2TEG&[#[16*W:]+Y+N-RG*+N7D
M%@7YE;<KVO6C20:;RQ-W=O8?,GU0(;I8Z0_KM'JM_EVEII+OG3NXN&,R5N%G
MCR)'F34Q35GDU,LR,M-?;AWG,'1[9?>"^[Q=LXYY=A81/K4N:E?LR^G9'==)
MLC%PYS=!S&X3'Y;)6:;-QUCA;(+NY240ASN)!Q"E+&)G!7Z]%X+M-EMG<;;9
MK+=;S<M?+8M<8M[F*",@3D->-<+&GSS5(6.,RA46X)F(TUQ;2-$O4*R,];@5
M&E@!U^*M//[`*Y5SQ[NN1C6]<;[A$;-8N8N'N65UC)7/[3S@:U2Z0TW.EQ;<
M6MWJ=>;8M#V.<BF;K'E;(LM(NXY4&DN2.5;INW!"L'&/L<S[;RR"?8(MAW%&
MMV6>/:#)$Z)\U:&*20W;1HQ%UZ`"*XU1&56*(3*M,1T7`,(A<:<Q'49:EH3J
MH/BIE7I7IUPN?%B$RYGCNT2\5:5Y*J/<BWM&K4=@^U9>]Q%2"Z6Y[KSVXW^7
MS"LZ(XL[K1W2S*)3)!KRC!BT(JT_<3K#X:YS.XWF3?MO@FA"7JWUF9)B+80M
M+Z40M1%"MQ)`(Q``\A,PC=V*OZ07.S<F0S("//K6I\M*T&F@!(I3,YT)ZTQ_
"_]D_
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
